Published in Haematologica on June 13, 2016
XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol (2017) 0.75
Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals. Elife (2017) 0.75
Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export. Oncotarget (2016) 0.75
Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. J Pathol Transl Med (2017) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med (1998) 8.24
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood (2011) 7.43
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev (2008) 3.57
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood (2005) 2.92
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood (2012) 2.27
Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet (2014) 2.02
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood (2009) 1.92
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene (2006) 1.79
Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol (2005) 1.77
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood (2013) 1.72
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood (2014) 1.71
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol (2013) 1.68
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood (2015) 1.68
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia (2013) 1.66
Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood (2002) 1.53
Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol (2015) 1.48
The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood (2011) 1.47
Hodgkin lymphoma. J Clin Invest (2012) 1.41
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood (2002) 1.38
STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget (2013) 1.35
FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood (2012) 1.31
Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res (2012) 1.26
The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci (2013) 1.25
Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol (2009) 1.18
Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res (2014) 1.17
Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol (2014) 1.10
Part II: Hodgkin's lymphoma--diagnosis and treatment. Lancet Oncol (2004) 1.08
Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma. Clin Cancer Res (2011) 0.97
Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer (2003) 0.97
Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma. Haematologica (2009) 0.96
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer (2015) 0.92
The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia (2014) 0.91
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. Clin Cancer Res (2016) 0.89
Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. Blood (2014) 0.87
Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget (2015) 0.83
Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica (2015) 0.82
Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol (2015) 0.81
Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma (2016) 0.81
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer (2015) 0.79
Identification of a nuclear export sequence in the MHC CIITA. J Immunol (2015) 0.78
Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma. Genes Chromosomes Cancer (2015) 0.76
Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget (2015) 0.83
The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma. Oral Oncol (2014) 0.77
Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study. J Mol Diagn (2017) 0.75